ACQUISITIONS - Narrative (Details) - USD ($)				1 Months Ended	3 Months Ended			12 Months Ended			24 Months Ended
	Aug. 31, 2024	Jun. 11, 2024	Jun. 16, 2023	Mar. 31, 2024	May 31, 2025	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2025	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2024
Business Combination [Line Items]
Payment for contracts payable								$ 1,576,000	$ 2,500,000	$ 0
Asset impairment charges					$ 77,200,000			77,221,000	0	500,000
Net income								64,718,000	$ (9,954,000)	$ (9,961,000)
Immunetrics
Business Combination [Line Items]
Purchase price			$ 15,255,000
Payment for contracts payable				$ 2,500,000				$ 1,600,000
Expected tax deductible amount			$ 0
Acquired finite-lived intangible assets, weighted average useful life			7 years 6 months
Asset impairment charges					3,900,000
Revenue							$ 1,300,000
Post acquisition revenue							$ (400,000)
Immunetrics | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Acquisition-Related Cost
Business Combination [Line Items]
Net income											$ 2,900,000
Immunetrics | Bonus Compensation
Business Combination [Line Items]
Net income											1,600,000
Immunetrics | Professional Fees
Business Combination [Line Items]
Net income											1,300,000
Pro-Ficiency
Business Combination [Line Items]
Purchase price	$ 100,162,000	$ 100,389,000
Expected tax deductible amount		0
Acquired finite-lived intangible assets, weighted average useful life			5 years 3 months 18 days
Excess cash adjustment		227,000
Deferred tax liabilities		$ 956,000
Impairment charges for its indefinite lived intangible assets					$ 72,200,000
Revenue						$ 2,300,000
Post acquisition revenue						$ (1,900,000)
Pro-Ficiency | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Acquisition-Related Cost
Business Combination [Line Items]
Net income											$ 2,300,000